readthroughSign in
Nov 12, 2026Partnership

Tempest Therapeutics exercises option for Senlang's CD7 lentiviral CAR-T platform

The move follows early Phase 1 data in 13 relapsed/refractory multiple myeloma patients treated with lead candidate TPST-4903.

Tempest Therapeutics announced on November 11, 2026 that it had exercised its option under an agreement with Hebei Senlang Biotechnology Co., Ltd. to secure an exclusive license to develop and commercialize Senlang's CD7-targeted lentiviral vector platform and associated in vivo CAR-T candidates worldwide, outside of China.1

The platform works alongside Tempest's existing delivery technology. The CD7-targeted lentiviral platform is designed to deliver CAR payloads into a patient's own immune cells, complementing Tempest's existing lipid nanoparticle (LNP) delivery platform, for in vivo generation of antigen-directed CAR-T cells.1 The lead program, originally named SL4903, is being redesignated TPST-4903, a BCMA/GPRC5D dual-targeting candidate under study in relapsed or refractory multiple myeloma.1

Regarding the underlying trial, at the data cutoff for the current analysis, 13 patients in the DELIVER-1 study had received TPST-4903, a population that includes heavily pretreated patients with relapsed or refractory multiple myeloma, including those with extramedullary disease and those who had previously received a BCMA-targeted CAR-T therapy.1 Tempest said the data are still preliminary and that longer follow-up will be needed before the risk and benefit profile can be fully assessed, with plans to present full results at a scientific conference.

The option itself traces back to September. Tempest first disclosed the exclusive option agreement with Senlang in September 2026.1 The newly exercised license carries financial and development commitments spelled out in that original agreement. The underlying study, DELIVER-1 (NCT07586709), is a single-center, open-label Phase 1 dose-escalation trial enrolling patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.